Cargando…

Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas

Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous lymphomas with poor overall prognosis, particularly in the setting of relapsed/refractory PTCL. Given the limited efficacy of current therapies, several different novel therapies encompassing multiple different mechanisms of action hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Braunstein, Zachary, Ruiz, Miguel, Hanel, Walter, Shindiapina, Polina, Reneau, John C., Brammer, Jonathan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225101/
https://www.ncbi.nlm.nih.gov/pubmed/35743749
http://dx.doi.org/10.3390/jpm12060964
_version_ 1784733536818823168
author Braunstein, Zachary
Ruiz, Miguel
Hanel, Walter
Shindiapina, Polina
Reneau, John C.
Brammer, Jonathan E.
author_facet Braunstein, Zachary
Ruiz, Miguel
Hanel, Walter
Shindiapina, Polina
Reneau, John C.
Brammer, Jonathan E.
author_sort Braunstein, Zachary
collection PubMed
description Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous lymphomas with poor overall prognosis, particularly in the setting of relapsed/refractory PTCL. Given the limited efficacy of current therapies, several different novel therapies encompassing multiple different mechanisms of action have been evaluated for relapsed and refractory PTCLs. In this review, we explore the current standard of care for relapsed/refractory PTCL, and evaluate in depth novel and emerging therapies, their scientific basis, and current trials for relapsed/refractory PTCL.
format Online
Article
Text
id pubmed-9225101
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92251012022-06-24 Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas Braunstein, Zachary Ruiz, Miguel Hanel, Walter Shindiapina, Polina Reneau, John C. Brammer, Jonathan E. J Pers Med Review Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous lymphomas with poor overall prognosis, particularly in the setting of relapsed/refractory PTCL. Given the limited efficacy of current therapies, several different novel therapies encompassing multiple different mechanisms of action have been evaluated for relapsed and refractory PTCLs. In this review, we explore the current standard of care for relapsed/refractory PTCL, and evaluate in depth novel and emerging therapies, their scientific basis, and current trials for relapsed/refractory PTCL. MDPI 2022-06-13 /pmc/articles/PMC9225101/ /pubmed/35743749 http://dx.doi.org/10.3390/jpm12060964 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Braunstein, Zachary
Ruiz, Miguel
Hanel, Walter
Shindiapina, Polina
Reneau, John C.
Brammer, Jonathan E.
Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas
title Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas
title_full Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas
title_fullStr Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas
title_full_unstemmed Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas
title_short Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas
title_sort recent advances in the management of relapsed and refractory peripheral t-cell lymphomas
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225101/
https://www.ncbi.nlm.nih.gov/pubmed/35743749
http://dx.doi.org/10.3390/jpm12060964
work_keys_str_mv AT braunsteinzachary recentadvancesinthemanagementofrelapsedandrefractoryperipheraltcelllymphomas
AT ruizmiguel recentadvancesinthemanagementofrelapsedandrefractoryperipheraltcelllymphomas
AT hanelwalter recentadvancesinthemanagementofrelapsedandrefractoryperipheraltcelllymphomas
AT shindiapinapolina recentadvancesinthemanagementofrelapsedandrefractoryperipheraltcelllymphomas
AT reneaujohnc recentadvancesinthemanagementofrelapsedandrefractoryperipheraltcelllymphomas
AT brammerjonathane recentadvancesinthemanagementofrelapsedandrefractoryperipheraltcelllymphomas